药物剂型演进视角下药剂学叙事教学的思路与设计
关键词:
药剂学, 故事化教学, 剂型演进, 课程思政, 叙事教学法摘要
药剂学是药学专业的核心课程，具有知识点密集、概念抽象、公式繁杂等特点，传统讲授式教学难以激发学生的学习兴趣和学科认同感。本文提出将“故事化叙事”（Narrative Pedagogy）引入药剂学课堂，以药物发现与剂型演进为主线，构建了涵盖“药物发现—剂型设计”的故事素材体系，包括阿司匹林200年剂型传奇、胰岛素百年递送攻坚、紫杉醇纳米制剂突破和青蒿素中医药智慧等四个典型案例。文章进一步设计了“故事导入—知识嵌入—思维延伸”的三段式教学策略，探索了如何将科学精神、工匠精神和文化自信等课程思政元素自然融入专业教学的有效途径。
参考
[1] Irby DH. Excellence in clinical teaching: knowledge transformation and development required. Medical Education, 2014, 48(8): 757–764.
[2] Charon R. Narrative medicine: a model for empathy, reflection, profession, and trust[J]. JAMA, 2001, 286(15): 1897–1902.
[3] Elmali F, Staiger C, Tekiner H. Can pharmaceutical history courses contribute in building future pharmacy leaders? A preliminary study from Erciyes University, Turkey[J]. Pharmazie, 2015, 70(11): 753–754.
[4] Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots–A concise summary. Vascular Pharmacology, 2019, 114: 1–8.
[5] Rainsford KD. Aspirin and Related Drugs. London: Taylor & Francis, 2004.
[6] Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology, 1971, 231(25): 232–235.
[7] Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Sciences, 1996, 143(1–2): 1–13.
[8] Mathieu C, Martens PJ, Vangoitsenhoven R. One hundred years of insulin therapy. Nature Reviews Endocrinology, 2021, 17(10): 715–725.
[9] Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I. Protamine insulinate. Acta Medica Scandinavica, 1936, 90(5–6): 678– 684.
[10] Goeddel DV, Kleid DG, Bolivar F, et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proceedings of the National Academy of Sciences, 1979, 76(1): 106–110.
[11] Howey DC, Bowsher RR, Brunelle RL, et al. [Lys(B28), Pro(B29)]-human insulin: A rapidly absorbed analog of human insulin. Diabetes, 1994, 43(3): 396–402.
[12] Lepore M, Pampanelli S, Cordoni C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes, 2000, 49(12): 2142–2148.
[13] Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, 2012, 379(9833): 2228–2244.
[14] Klonoff DC. Afrezza inhaled insulin: the fastest-acting FDA- approved insulin on the market has favorable properties. Journal of Diabetes Science and Technology, 2014, 8(6): 1071–1073.
[15] Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature, 1979, 277(5700): 665– 667.
[16] Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer, 2001, 37(13): 1590–1598.
[17] Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 2005, 23(31): 7794–7803.
[18] Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nature Medicine, 2011, 17(10): 1217– 1220. DOI: 10.1038/nm.2471.
